Article

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers

Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA.
Experimental and Clinical Psychopharmacology (Impact Factor: 2.63). 05/2009; 17(2):122-9. DOI: 10.1037/a0015700
Source: PubMed

ABSTRACT Topiramate, an anticonvulsant medication, is an efficacious treatment for alcohol dependence. To date, little is known about genetic moderators of side effects from topiramate. The objective of this study was to examine 3 single nucleotide polymorphisms (SNPs) of the glutamate receptor GluR5 gene (GRIK1) as predictors of topiramate-induced side effects in the context of a laboratory study of topiramate. Heavy drinkers (n=51, 19 women and 32 men), 75% of whom met criteria for an alcohol use disorder, completed a 5-week dose escalation schedule to a target dose of either 200 or 300 mg or matched placebo. The combined medication groups were compared with placebo-treated individuals for side effects at target dose. Analyses revealed that an SNP in intron 9 of the GRIK1 gene (rs2832407) was associated with the severity of topiramate-induced side effects and with serum levels of topiramate. Genes underlying glutamatergic neurotransmission, such as the GRIK1 gene, may help predict heterogeneity in topiramate-induced side effects. Future studies in larger samples are needed to more fully establish these preliminary findings.

Download full-text

Full-text

Available from: Robert Swift, Sep 01, 2015
0 Followers
 · 
171 Views
 · 
66 Downloads
  • Source
    • "In the subsample of European Americans (n = 122), topiramate was effective in reducing heavy drinking days only in rs2832407 C-allele homozygotes . In addition, a previous pharmacogenetic analysis of the human laboratory pilot study mentioned previously (Miranda et al., 2008) showed that rs2832407 was associated with the severity of topiramate-induced side effects (Ray et al., 2009). The RCT by Kranzler et al. (2014) did not find an effect of the SNP on adverse events, suggesting that the kainate receptor does not play a unique role in mediating topiramate-related adverse effects. "
    The International Journal of Neuropsychopharmacology 06/2014; 17(10):1-4. DOI:10.1017/S1461145714000790 · 5.26 Impact Factor
    • "The changes in mRNA levels do not directly address whether protein levels of glutamate receptors have changed but this could potentially be verified by Western blot analysis of protein expression. The data complement previous studies on the effects of alcohol on glutamate signaling (Wernicke et al., 2003; Petrakis et al., 2004; Rujescu et al., 2005; Kim et al., 2006; Preuss et al., 2006; Kranzler et al., 2009; Ray et al., 2009; Ridge et al., 2009) and provide further evidence for long-term changes of glutamate receptors in the central nervous system by chronic alcohol consumption. The hippocampus is important for learning and memory (Nicoll and Roche, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glutamate is the main excitatory transmitter in the human brain. Drugs that affect the glutamatergic signaling will alter neuronal excitability. Ethanol inhibits glutamate receptors. We examined the expression level of glutamate receptor subunit mRNAs in human post-mortem samples from alcoholics and compared the results to brain samples from control subjects. RNA from hippocampal dentate gyrus (HP-DG), orbitofrontal cortex (OFC), and dorso-lateral prefrontal cortex (DL-PFC) samples from 21 controls and 19 individuals with chronic alcohol dependence were included in the study. Total RNA was assayed using quantitative RT-PCR. Out of the 16 glutamate receptor subunits, mRNAs encoding two AMPA [2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid] receptor subunits GluA2 and GluA3; three kainate receptor subunits GluK2, GluK3 and GluK5 and five NMDA (N-methyl-D-aspartate) receptor subunits GluN1, GluN2A, GluN2C, GluN2D, and GluN3A were significantly increased in the HP-DG region in alcoholics. In the OFC, mRNA encoding the NMDA receptor subunit GluN3A was increased, whereas in the DL-PFC, no differences in mRNA levels were observed. Our laboratory has previously shown that the expression of genes encoding inhibitory GABA-A receptors is altered in the HP-DG and OFC of alcoholics (Jin et al., 2011). Whether the changes in one neurotransmitter system drives changes in the other or if they change independently is currently not known. The results demonstrate that excessive long-term alcohol consumption is associated with altered expression of genes encoding glutamate receptors in a brain region-specific manner. It is an intriguing possibility that genetic predisposition to alcoholism may contribute to these gene expression changes.
    Frontiers in Cellular Neuroscience 01/2014; 8:11. DOI:10.3389/fncel.2014.00011 · 4.18 Impact Factor
  • Source
    • "Such findings on safety and mechanisms are vital to deciding whether to invest resources for efficacy testing for a putative addiction medication . Our team has used human laboratory paradigms to test several medications for addiction, including naltrexone (Ray, Bujarski, Chin, & Miotto, 2012; Ray & Hutchison, 2007), topiramate (Miranda et al., 2008; Ray et al., 2009), quetiapine (Moallem & Ray, 2012; Ray, Chin, Heydari, & Miotto, 2011), and varenicline (Ray et al., 2014, 2013). Given the new opportunities presented by recent discoveries on the role of neuroinflammation in addiction as well as new advancements in the technology of medication development , including the refinement of powerful human laboratory models, the stage is set for the discovery of novel treatments for substance use disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have implicated neuroinflammatory processes in the pathophysiology of various psychiatric conditions, including addictive disorders. Neuroimmune signaling represents an important and relatively poorly understood biological process in drug addiction. The objective of this review is to update the field on recent developments in neuroimmune therapies for addiction. First, we review studies of neuroinflammation in relation to alcohol and methamphetamine dependence followed by a section on neuroinflammation and accompanying neurocognitive dysfunction in HIV infection and concomitant substance abuse. Second, we provide a review of pharmacotherapies with neuroimmune properties and their potential development for the treatment of addictions. Pharmacotherapies covered in this review include ibudilast, minocycline, doxycycline, topiramate, indomethacin, rolipram, anakinra (IL-1Ra), peroxisome proliferator-activated receptor agonists, naltrexone, and naloxone. Lastly, summary and future directions are provided with recommendations for how to efficiently translate preclinical findings into clinical studies that can ultimately lead to novel and more effective pharmacotherapies for addiction.
    International Review of Neurobiology 01/2014; 118C:381-401. DOI:10.1016/B978-0-12-801284-0.00012-9 · 2.46 Impact Factor
Show more